American Association for Cancer Research
00085472can191415-sup-221749_2_supp_5808355_pyntck.xlsx (439.71 kB)

Supplemental Tables S1-5 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

Download (439.71 kB)
posted on 2023-03-31, 02:45 authored by Grace E. Coggins, Alvin Farrel, Komal S. Rathi, Colin M. Hayes, Laura Scolaro, Jo Lynne Rokita, John M. Maris

Table S1 includes MYCN amplification and chromosome 11q status across a panel of 16 neuroblastoma cell lines. Table S2-4 include differentially-expressed genes identified in each of the three differential expression analyses. Table S5 includes unique differentially expressed genes between NLF sgCon + DMSO and NLF YAP1-/- #4 + Tram.





Relapsed neuroblastomas are enriched with activating mutations of the RAS–MAPK signaling pathway. The MEK1/2 inhibitor trametinib delays tumor growth but does not sustain regression in neuroblastoma preclinical models. Recent studies have implicated the Hippo pathway transcriptional coactivator protein YAP1 as an additional driver of relapsed neuroblastomas, as well as a mediator of trametinib resistance in other cancers. Here, we used a highly annotated set of high-risk neuroblastoma cellular models to modulate YAP1 expression and RAS pathway activation to test whether increased YAP1 transcriptional activity is a mechanism of MEK1/2 inhibition resistance in RAS-driven neuroblastomas. In NLF (biallelic NF1 inactivation) and SK-N-AS (NRAS Q61K) cell lines, trametinib caused a near-complete translocation of YAP1 protein into the nucleus. YAP1 depletion sensitized neuroblastoma cells to trametinib, while overexpression of constitutively active YAP1 protein induced trametinib resistance. Mechanistically, significant enhancement of G1–S cell-cycle arrest, mediated by depletion of MYC/MYCN and E2F transcriptional output, sensitized RAS-driven neuroblastomas to trametinib following YAP1 deletion. These findings underscore the importance of YAP activity in response to trametinib in RAS-driven neuroblastomas, as well as the potential for targeting YAP in a trametinib combination. High-risk neuroblastomas with hyperactivated RAS signaling escape the selective pressure of MEK inhibition via YAP1-mediated transcriptional reprogramming and may be sensitive to combination therapies targeting both YAP1 and MEK.

Usage metrics

    Cancer Research



    Ref. manager